New Delhi: After Covishield and Covaxin, a third vaccine was released in the country for the Indian market on Friday and the same price has been kept for the centre, states and market instead of the last two vaccines separately for the centre.
Indian pharmaceutical company Dr Reddy’s Laboratories said on Friday that it has released the Covid-19 vaccine Sputnik V in the Indian market. As its limited introduction, the first vaccine of Sputnik-V was injected in Hyderabad.
The company said that the retail price of one dose of this imported medicine is Rs 948. The cost of the vaccine with GST at the rate of five per cent on this is Rs 995.40 per dose.
Dr Reddy’s Laboratories said in a statement, “The imported vaccine is currently priced at Rs. 948 and above that GST will be payable at the rate of five per cent.” After the start of production at the local level, there may be some reduction in the price.
The company said that the first shipment of vaccine Sputnik V imported from Russia reached India on 1 May. This vaccine was approved on 13 May 2021 from the Central Pharmaceutical Laboratory, Kasauli.
More consignment of this medicine is going to reach India in the coming months. After that, its supply will also start from Indian manufacturing partners.
Dr Reddy’s said that he is in touch with his six manufacturing partners in India for a timely and uninterrupted supply of vaccines. The Hyderabad-based company said it would work closely with all sides of the government and the private sector to cooperate in the national vaccination campaign so that the Sputnik V vaccine could be delivered on a wider scale.
GV Prasad, co-chairman and managing director of Dr Reddy’s, said, “Vaccination is the most effective weapon in fighting Covid-19 among the growing cases of coronavirus in India. It is our biggest priority to help keep Indians healthy and safe by participating in vaccination campaigns in India.
So far, only two vaccines are being used in the country. Covishield being made by Bharat Biotech’s Covoxin and Serum Institute of India is being used primarily.
The Indian Drug Controller General of DCGI in January approved the emergency use of the Oxford-AstraZeneca Vaccine Covishield and Bharat Biotech’s Covaxine manufactured by the world’s largest vaccine manufacturer, Pune-based Serum Institute of India.
Bharat Biotech, along with the Indian Council of Medical Research (ICMR), has developed cocaine. At the same time, the Serum Institute of India has partnered with the British-Swedish company AstraZeneca and the University of Oxford to produce ‘Covishield’.
In the same month, approval was granted in India for limited emergency use of Covid-19 vaccine ‘Sputnik V ‘ manufactured in Russia . ‘Sputnik V’ is the third vaccine used against the Coronavirus in India. In India, it will be manufactured by Dr Reddy’s Laboratories.
Let us know that on January 16, the nationwide Covid-19 vaccination campaign was started in India. In the first phase of vaccination, frontline workers and health workers were vaccinated.
After that, the second phase of Covid-19 vaccination has started on March 1. In this phase, the elderly above 60 years and those above 45 years who have serious health problems are being vaccinated.
Last May vaccination of the 18 to 44 year age group also has begun.